Clinical Trial Update: Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial evaluating CD19/CD20 CAR/TRuC-T therapy for relapsed/refractory B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CD19/CD20 CAR/TRuC-T

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Relapsed/Refractory B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING